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16 instead of serine ( Fig. 1 ). In the mammals studied so far, glucagon has been located mainly in the Gut glucagon-like immunoreactants pancreas, where it is synthesised in the A cells of the islets of Langerhans (Bussolati et al., 1971) . A well The term gut glucagon-like immunoreactant is used characterised gastric glucagon has, however, been for any gut peptide which reacts with an antilocated in A-like cells in the canine gastric mucosa glucagon serum to prevent the binding of radio- (Vranic et al., 1976) . iodinated glucagon to the antibodies in the serum. The first description of a substance in the gastro-The existence of gut GLIs and the pattern of their intestinal tract with glucagon-like activities was secretion by the intestine was shown in the 1960s, the demonstration by Sutherland and Gut GLIs are found in the intestinal L cell, which is located in the intestinal mucosa and which differs from the pancreatic A cell (Orci et al., 1968) . The L cell is found throughout the small intestine and is particularly frequent in the lower small intestine and colon. This distribution of the L cell is in agreement with the distribution of gut GLIs in extracts of the different sections of the intestinal tract (Bloom and Polak, 1978) .
SIZE
Gut GLIs extracted from the intestine can be separated into two classes by gel permeation chromatography, with approximate molecular weights of 6000 and 4000, respectively (Valverde et al., 1970) . Circulating gut GLIs have a similar size distribution. The extracted gut GLIs can be further fractionated, particularly by isoelectric focusing (Moody et al., 1975) . The plurality of gut GLIs that can be demonstrated is probably the result of modifications occurring during extraction and fractionation, and does not reflect the forms found in vivo.
BIOLOGICAL EFFECTS
No biologically active highly purified gut GLI has so far been described. Crude duck gut GLI with a molecular weight of 6000 to 13 000 was found to inhibit the glucagon-induced lipolysis of duck adipocytes (Krug and Mialhe, 1977) . Partially purified porcine gut GLI with a molecular weight of approximately 4000 has been found to inhibit the binding of 1251-glucagon to liver plasma membranes, to stimulate liver plasma membrane adenyl cyclase (Bataille et al., 1974; Moody et al., 1975) , and also to stimulate insulin release (Tanaka et al., 1977) . With the exception of the displacement of 1251_ glucagon from liver plasma membranes, these effects could well have been caused by a contaminating peptide such as VIP.
IMMUNOCHEMISTRY
The detailed structures of gut GLIs are, as yet, unknown but a consideration of the immunochemistry of glucagon provides a background for their study. It was appreciated early in the development of the radioimmunoassay for glucagon that the peptide is a poor antigen and that most antiglucagon sera bound not only glucagon but also gut GLIs (Heding, 1972) . Assan and Slusher (1972) pointed out that the antisera which react with both gut GLIs and glucagon are directed towards the N terminal and central portions of the glucagon molecule. In contrast, the antisera which react with glucagon alone react with the C terminal portion of the glucagon molecule. This description of two antigenic sites in the glucagon molecule has now been extended. Heding et al. (1976) found that duck glucagon and glucagon modified at position 27 react very poorly with antiglucagon sera directed towards the C terminal portion of the molecule, and proposed that the C terminal antigenic site of glucagon involves positions 24 to 29. A probable location of the N terminal antigenic site, which Assan and Slusher (1972) suggested as being in the region 9 to 23 and Heding et al. (1976) in the region 2 to 23, has recently been defined as follows. It was suggested (Moody et al., 1978) that the N terminal antigenic site was in the glucagon sequence 11 to 14, because that is the only extensive part of the glucagon sequence which is not found in secretin, VIP, or GIP which does not react with antiglucagon sera. Yanaihara et al. (1979) , on the basis of studies with synthetic fragments of glucagon, has proposed that the N terminal immunoreactive site in glucagon is located in the sequence 1 to 16. Duck glucagon, with a threonine instead of serine at position 16, has much the same immunoreactivity with N terminal specific antiglucagon sera as porcine glucagon and turkey glucagon. The antiglucagon sera that react with glucagon, avian glucagons, and gut GLIs therefore probably react with the glucagon sequence 11 to 15, whereas the antiglucagon sera that react with mammalian glucagons react with the glucagon sequence 24 to 29. The amino-acid sequences involved in these proposed immunoreactants are shown in Fig. 1 .
Glucagon coupled to albumin with glutaraldehyde evokes the formation of a very high percentage of antiglucagon (24 to 29) sera (Garaud et al., 1976) . Since glutaraldehyde probably reacts with the lysine residue at position 12, thereby disrupting the structure of glucagon in this region, this finding provides indirect support for the proposal that glucagon has an antigenic site in the region 11 to 15.
The detection of gut GLIs with an antiglucagon (11 to 15) serum shows that the sample contains a peptide or peptides with an immunoreactive site similar to that of glucagon (11 to 15), but it does not provide any information about the structure of the molecule outside the immunoreactant.
It is of particular interest to know whether the gut GLIs have in common with glucagon only an immunoreactive site corresponding to the glucagon sequence 11 to 15 or whether they have an extensive chemical similarity to glucagon.
STR UCT URE
The isolation of a porcine protein, gut GLI-1 (also known as glicentin), with full immunoreactivity with antiglucagon (11 to 15) sera, but devoid of 27 28 29 Fig. 2 The 3 amino-acids from the C Met -Asn -Thr terminus ofglucagon (Bromer et al., 1956) Met -Asn -Thr -Lys -Arg -Asn-Asn-Lys-Asn-le -Ala are aligned with the partial C terminal Met -Asn -Thr -Lys -Arg -Asn -Ays-ysn-Asn-le -Ala sequences of a proglucagon fragment (Tager Met -Asn -Thr-Lys-Arg -Asn -Lys-Asn-Asn -lle -Ala and Steiner, 1973) and ofporcine glicentin (Jacobsen et al., 1977) . The difference between the latter two sequences is underlined. reactivity with antiglucagon (24 to 29) sera, has provided us with the opportunity to study in detail the relationship of a gut GLI to glucagon.
Glicentin contains 100 amino-acids, including all of those found in porcine glucagon . The eleven residues from the C terminal end consist of the three C terminal amino-acids of glucagon with an octapeptide attached to the C terminal threonine (Jacobsen et al., 1977) . The same eight amino-acids were also described in the C terminal octapeptide of a proposed proglucagon fragment by Tager and Steiner (1973) . The C terminal sequences of glicentin and this proglucagon fragment are shown in Fig. 2 . The two sequences are closely related, the only difference being an inversion of the lysine and arginine at positions 3 and 4 from the C terminal alanine of glicentin. Further sequence studies have supported the concept that glicentin contains the full sequence of glucagon, placed so that the 37 amino-acids from the C terminal end of glicentin consist of glucagon prolonged by the octapeptide shown in Fig. 2 . If the proposed structure is correct, then gut GLIs smaller than glicentin will be found to consist of the sequence of glucagon modified by N and C terminal additions or deletions.
It has been proposed (Moody et al., 1978) that the C terminal octapeptide in some way 'masked' the immunoreactant present in the sequence corresponding to the glucagon sequence 24 to 29, leaving glicentin only one immunoreactive site in common with glucagon, corresponding to glucagon 11 to 15. Proof of this postulate has been provided by Yanaihara et al. (1979) , who synthesised glucagon (17 to 29) attached to the C terminal octapeptide of glicentin, and glucagon (23 to 29) attached to the C terminal octapeptide of the proglucagon fragment of Tager and Steiner (1973) . Neither of these peptides reacted with an antiglucagon (24 to 29) serum, but synthetic glucagon (19 to 29) had 31 % molar immunoreactivity with this antiserum.
Highly purified glicentin coupled to albumin with glutaraldehyde was used to raise antiglicentin sera in rabbits. One of these sera, R64, which does not bind glucagon has been used for immunocytochemical studies of the distribution of glicentin, using indirect immunofluorescence and peroxidase techniques. R64 binds to the secretory granules in the pancreatic A cell and the intestinal L cell in several species (Ravazzola et al., 1979) . These observations have been confirmed by the detection of immunoreactive glicentin in pancreatic extracts (Moody et al., 1978) . The immunocytochemical and radioimmunological evidence led us to propose that a glicentinlike peptide is a glucagon precursor, and that the initial genetically determined product in both A and L cells is a glicentin-like molecule which is cleaved to glucagon in the A cell and to smaller gut GLIs in the L cell (Moody et al., 1978) .
Quantitative estimation of the immunoreactive (IR) glicentin content of rat and human pancreas, and of a single glucagonoma were disappointing. It was found that the IR glicentin was only one part per thousand of the total GLI, although in all cases immunoreactive glicentin was found to have a similar size to 1251-glicentin by gel filtration on Sephadex G50. These very low levels were at variance with the intense immunocytochemical staining of the A cell by R64. It is possible that antibodies with different specificities were involved in the immunocytochemical and immunochemical reactions. Alternatively, the fixation techniques used in the immunocytochemical studies could have enhanced the immunoreactivity of small amounts of glicentin.
Initial studies of IR glicentin in human plasma led us to believe that it could be detected, and that levels rose after an oral glucose load provided that the gut GLI rose to above 300 pmol/l. More recent studies with an improved assay have failed to support these findings, and we do not think at present that the radioimmunoassay for porcine glicentin can detect substantial amounts of immunoreactive glicentin in human plasma from peripheral veins.
In the pig, fasting levels of 95 pmol/l have been measured, which increase significantly after feeding and remain raised for up to 3 hours or more after feeding (Table) .
These findings suggest that a peptide containing one of the immunoreactive sites of glicentin is released by the porcine L cell after feeding. Further investigation is required to establish whether IR glicentin is associated with intact glicentin or with a small peptide. The gut GLIs probably consist of an amino-acid sequence basically identical with that of glucagon but modified by extension or shortening of the C and N terminal ends. This proposed structure of the gut GLIs explains why they react with antisera to glucagon (11 to 15) and why gut GLIs with a size similar to that of glucagon exert glucagon-like biological effects. The gut GLIs are therefore the most glucagon-like of all the peptides discussed here. The proposed structure does not, however, provide information about the role of endogenous gut GLIs. It has been proposed that gut GLIs control the growth and function of the upper small intestine (Bloom and Polak, 1977) but proof of this proposal awaits the isolation and characterisation of biologically active gut GLIs.
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